Shares of BridgeBio Pharma Inc.
BBIO,
gained 5.5% premarket on Tuesday after the company announced that its investigational treatment for children with achondroplasia, a bone growth disorder that causes disproportionate short stature, resulted in significant growth in a clinical trial. More than 80% of children in the study responded to the treatment, infigratinib, based on at least a 25% increase in annual height velocity, the company said in a release. Based on the positive phase 2 study results, BridgeBio said it is currently enrolling children in a pivotal phase 3 trial.
